scholarly journals Modelling the ATP-binding site of oncogene products, the epidermal growth factor receptor and related proteins

FEBS Letters ◽  
1984 ◽  
Vol 175 (2) ◽  
pp. 387-392 ◽  
Author(s):  
Michael J.E. Sternberg ◽  
William R. Taylor
1996 ◽  
Vol 16 (11) ◽  
pp. 6009-6019 ◽  
Author(s):  
J H Ludes-Meyers ◽  
M A Subler ◽  
C V Shivakumar ◽  
R M Munoz ◽  
P Jiang ◽  
...  

The human epidermal growth factor receptor (EGFR) promoter is activated by both wild-type and tumor-derived mutant p53. In this communication, we demonstrate that EGFR promoter sequence requirements for transactivation by wild-type and mutant p53 are different. Transient-expression assays with EGFR promoter deletions identified a wild-type human p53 response element, 5'-AGCTAGACGTCCGGGCAGCCCCCGGCG -3', from positions --265 to --239. Electrophoretic mobility shift analysis and DNase I footprinting assays indicated that wild-type p53 binds sequence specifically to the response element. Using circularly permuted DNA fragments containing the p53-binding site, we show that wild-type p53 binding induces DNA bending at this site. We further show that the EGFR promoter is also activated by tumor-derived p53 mutants p53-143A, p53-175H, p53-248W, p53-273H, and p53-281G. However, the transactivation by mutant p53 does not require the wild-type p53-binding site. The minimal EGFR promoter from positions --104 to --20 which does not contain the wild-type p53-binding site is transactivated by the p53 mutants but not by the wild-type protein, showing a difference in the mechanism of transactivation by wild-type and mutant p53. Transactivation of the EGFR promoter by p53 may represent a novel mechanism of cell growth regulation.


Sign in / Sign up

Export Citation Format

Share Document